LABORATORY RESEARCH A KRAB/KAP1-MicroRNA Cascade Regulates Erythropoiesis through Stage-Specific Control of Mitophagy During hematopoiesis, lineage- and stage-specific transcription factors work in concert with chromatin modifiers to direct the differentiation of all blood cells. Scientists explored the role of KRAB-containing zinc finger proteins and their cofactor KAP1 in this process. [Science] Abstract GSK3β Regulates Physiological Migration of Stem/Progenitor Cells via Cytoskeletal Rearrangement While glycogen synthase kinase-3β (GSK3β) is known to participate in hematopoietic stem and progenitor cell (HSPC) proliferation, the authors revealed an unexpected role in the preferential regulation of CXCL12-induced migration and steady-state egress of murine HSPCs, including long-term repopulating HSCs, over mature leukocytes. [J Clin Invest] Full Article Interferon-Gamma Impairs Proliferation of Hematopoietic Stem Cells in Mice Researchers demonstrated that the pro-inflammatory cytokine interferon-γ (IFN-γ) impairs maintenance of hematopoietic stem cells (HSCs) by directly reducing their proliferative capacity and that IFN-γ impairs restoration of HSC numbers upon viral infection. [Blood] Abstract Maintenance of the Hematopoietic Stem Cell Pool in Bone Marrow Niches by EVI1-Regulated GPR56 Acute myeloid leukemia (AML) with high ecotropic viral integration site-1 expression (EVI1high AML) is classified as a refractory type of leukemia with a poor prognosis. To provide new insights into the prevention and treatment of this disease, scientists identified the high expression of EVI1-regulated G protein-coupled receptor 56 (GPR56) and the association of high cell adhesion and anti-apoptotic activities in EVI1high AML cells. [Leukemia] Abstract Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells Investigators generated PIM1 transgenic mice (Pim1-Tx) over-expressing human PIM1 driven by vav hematopoietic promoter/regulatory elements. Compared to wild-type littermates, Pim1-Tx mice showed enhanced hematopoiesis as demonstrated by increased numbers of Lin−Sca-1+c-Kit+ hematopoietic stem/progenitor cells (HSCs) and cobblestone area forming cells, higher BrdU incorporation in long-term HSC population, and a better ability to reconstitute lethally irradiated mice. [Stem Cells] Abstract Introduction of Exogenous T-Cell Receptors into Human Hematopoietic Progenitors Results in Exclusion of Endogenous T-Cell Receptor Expression Scientists successfully generated MART-1-specific CD8 T cells from genetically modified human hematopoietic stem cells in a humanized mouse model. [Mol Ther] Abstract Lenograstim Compared to Filgrastim for the Mobilization of Hematopoietic Stem Cells in Healthy Donors The authors compared the efficacy of lenograstim and filgrastim in terms of number of circulating CD34+ cells/μL during the fifth day of granulocyte-colony-stimulating factor administration, the number of days of apheresis required to obtain the target cell dose, the median of CD34+ cells collected on the first day of apheresis, or the median number of total CD34+ cells collected at the end of the procedure, in a series of 146 healthy donors undergoing hematopoietic stem cell mobilization for allogeneic transplantation. [Transfusion] Abstract CLINICAL RESEARCH Outcomes of Transplantation Using Various Hematopoietic Cell Sources in Children with Hurler’s Syndrome after Myeloablative Conditioning Event free survival (EFS) after HLA matched sibling donor and 6/6 matched unrelated-cord blood (CB) were similar at 81%, 66% after 10/10 HLA matched unrelated donor (UD) and 68% after 5/6 matched CB. EFS was lower after transplantation of 4/6 matched unrelated CB and HLA mismatched UD. [Blood] Abstract | Press Release Nilotinib Is Associated with a Reduced Incidence of BCR-ABL Mutations versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to tyrosine kinase inhibitor therapy. Researchers examined the occurrence of treatment-emergent mutations and their impact on response in patients from the ENESTnd Phase III trial. [Blood] Abstract |